NeuroBo Pharmaceuticals News

NeuroBo Pharmaceuticals | EFFECT: Others

18:08

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 17 20:34

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Apr 17 04:36

NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Apr 13 04:09

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Apr 1 20:31

NeuroBo Pharmaceuticals | 10-K: Annual report

Mar 29 10:26

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 28 20:05

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 13 20:33

NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Woodworth Marshall H

Mar 5 10:21

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Mar 4 20:35

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 29 21:33

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Feb 14 21:56

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Feb 1 21:31

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

Jan 18 13:00

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 9 13:00

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Submits Ind Application to the Fda for a Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity

Dec 28, 2023 13:00

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 19, 2023 22:03

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc Posted an Updated Corporate Presentation

Dec 7, 2023 22:20

NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Tursi James Patrick

Dec 5, 2023 06:12

NeuroBo Pharmaceuticals: Q3 2023 Earnings Report

Nov 14, 2023 05:29